Preskoči na sadržaj
VuFind
English
Deutsch
Español
Français
Italiano
日本語
Nederlands
Português
Português (Brasil)
中文(简体)
中文(繁體)
Türkçe
עברית
Gaeilge
Cymraeg
Ελληνικά
Català
Euskara
Русский
Čeština
Suomi
Svenska
polski
Dansk
slovenščina
اللغة العربية
বাংলা
Galego
Tiếng Việt
Hrvatski
हिंदी
Հայերէն
Українська
Sámegiella
Монгол
Jezik
Sva polja
Naslov
Autor
Tema
Signatura
ISBN/ISSN
Oznaka
Pronađi
Napredno
Discordance between power Dopp...
Citiraj ovo
Pošalji tekstualnu poruku
Pošalji ovo e-mailom
Ispiši
Izvezi zapis
Izvezi u RefWorks
Izvezi u EndNoteWeb
Izvezi u EndNote
Stalna poveznica
Discordance between power Doppler and DAS28 assessment of remission induction in a randomised, placebo-controlled stud of infliximab therapy in early rheumatoid arthritis
Bibliografski detalji
Glavni autori:
Taylor, P
,
Steuer, A
,
McClinton, C
,
Blomley, M
,
Wagner, C
,
Marsters, P
,
Maini, R
Format:
Conference item
Izdano:
2005
Primjerci
Opis
Slični predmeti
Prikaz za djelatnike knjižnice
Opis
Sažetak:
Slični predmeti
Comparison of ultrasonographic assessment of synovitis and joint vascularity with radiographic evaluation in a randomized, placebo-controlled study of infliximab therapy in early rheumatoid arthritis.
od: Taylor, P, i dr.
Izdano: (2004)
Comparison of ultrasonographic assessment of synovitis and joint vascularity with radiological evaluation in a randomized, placebo-controlled study of infliximab therapy in early rheumatoid arthritis.
od: Taylor, P, i dr.
Izdano: (2003)
Comparison of remission induction in erosive early KA assessed by DAS28 calculated using either ESR or CRP in infliximab plus MTX combination therapy or MTX monotherapy
od: Taylor, P, i dr.
Izdano: (2005)
Kinetics of change in erosion scores as assessed by plain radiography and high frequency ultrasound in a randomised, controlled trial of infliximab plus MTX versus MTX only therapy in erosive early rheumatoid arthritis
od: Taylor, P, i dr.
Izdano: (2005)
Comparison of ultrasonographic measures of synovitis and radiographic assessment of structural damage over two years in a randomised, controlled trial of infliximab therapy in erosive early rheumatoid arthritis.
od: Taylor, P, i dr.
Izdano: (2004)